Operator
Greetings, and welcome to the Global Blood Therapeutics conference call. [Operator instructions] I would now like to turn the call over to Steven Immergut. Please, go ahead.
Steven Immergut
Senior Vice President, Head of Corporate Communications and Investor Relations
Thank you, and welcome to GBT s conference call to discuss the Company s financial results for the first quarter of 2021 and to provide a business update. I m Steven Immergut, head of communications and investor relations. Joining me on the call are Dr. Ted Love, our president and CEO, who will provide an update on our progress in the first quarter; Jeff Farrow, our chief financial officer, who will review our financial results; David Johnson, or DJ, our chief commercial officer, will give an update on the Oxbryta launch. Ted will then introduce Dr.
Good Day BIO February 26, 2021
Throughout Black History Month, Good Day BIO has been highlighting the accomplishments of Black trailblazers in science and biotechnology here’s a list of 20 you should know.
1. Dr. Akinwumi Adesina
Nigerian agricultural economist Dr. Akinwumi Adesina, Ph.D., won the 2017 World Food Prize for leading major policy change that’s helped millions of African farmers and improved nutrition across the continent. Since 2015, Dr. Adesina has served as president of the African Development Bank, where he works to end malnutrition and stunting.
To learn more about Dr. Akinwumi Adesina, click here.
Image
2. Alice Ball
Young chemist Alice Ball achieved a number of firsts including discovering the first treatment for leprosy. Ball was the first woman AND the first African American to earn a Master’s in chemistry from the College of Hawaii, in 1915. At 23 years old, she discovered how to safely inject chaulmoogra oil to use as a treatment for
Operator
Greetings, and welcome to Global Blood Therapeutics conference call. [Operator instructions] As a reminder, this conference is being recorded. I would now like to turn this conference over to Mr. Steven Immergut.
Please go ahead, sir. You may begin.
Steven Immergut
Senior Vice President, Head of Corporate Communications, and Investor Relations
Thank you, and welcome to GBT s conference call to discuss the company s financial results for the fourth-quarter and full-year 2020 and to provide a business update. I m Steven Immergut, head of communications and investor relations. Joining me on the call are Dr. Ted Love, our president and CEO, who will provide a high-level update on our progress in the fourth quarter and over the full-year 2020; jeff Farrow, our chief financial officer, who will provide an overview of our financial results; and David Johnson, or DJ, our chief commercial officer, who will give an update on the Oxbryta launch.
EMA begins review of GBT s sickle cell treatment Oxbryta
29th January 2021
The European Medicines Agency (EMA) has accepted a marketing authorisation application for Global Blood Therapeutic’s (GBT) Oxbryta (voxelotor).
GBT is aiming for the approval of Oxbryta to treat haemolytic anaemia in patients with sickle cell disease (SCD) who are 12 years of age and older.
Oxbryta is a first-in-class oral therapy, designed to inhibit haemoglobin polymerisation, which causes the sickling and destruction of red blood cells in SCD.
This process – known as sickling – causes haemolytic anaemia and blockages in capillaries and small blood vessels.
In turn, this can impact the flow of blood and oxygen throughout the body, with reduced oxygen delivered to tissues and organs which can lead to life-threatening complications.